Iterum Therapeutics has recently achieved a significant milestone with the FDA approval of Orlynvah, a groundbreaking treatment for uncomplicated urinary tract infections (UTIs) in adult women. This approval marks the first indication for Orlynvah and introduces the first oral penem in the United States, setting a new standard in the treatment of UTIs.
This development not only highlights Iterum Therapeutics' commitment to addressing unmet medical needs but also paves the way for new strategic partnerships. The approval of Orlynvah is a testament to the company's innovative approach to developing treatments that offer new hope to patients suffering from UTIs, providing a much-needed alternative to existing therapies.
